Stephen Bagley
YOU?
Author Swipe
View article: IMG-33. Unveiling glioblastoma heterogeneity with deep learning derived MRI subtyping: insights from the global ReSPOND consortium
IMG-33. Unveiling glioblastoma heterogeneity with deep learning derived MRI subtyping: insights from the global ReSPOND consortium Open
PURPOSE This study aims to identify distinct imaging subtypes of glioblastoma using multi-modal MRIs from the ReSPOND consortium, providing insights into tumor heterogeneity to inform personalized treatment approaches. METHODS We analyzed …
View article: DDDR-63. Immune remodeling in CSF and tumor predicts response to CAR T therapy in glioblastoma
DDDR-63. Immune remodeling in CSF and tumor predicts response to CAR T therapy in glioblastoma Open
Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor in adults. We previously reported results from a phase I clinical trial demonstrating that intracerebroventricular delivery of bivalent CAR T cells, targeting E…
View article: OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209
OS04.5.A A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209 Open
BACKGROUND FGFR genomic alterations occur in approximately 8% of gliomas. Inhibition of FGFR1-3 with pemigatinib showed antitumor activity in a multihistology basket trial (FIGHT-207) in which approximately 10% of participants (pts) had re…
View article: Intracranial metastases from solid tumors: Call to Action and Consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology Collaborative
Intracranial metastases from solid tumors: Call to Action and Consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology Collaborative Open
Intracranial metastases (ICM), specifically parenchymal brain metastases, remain a major clinical challenge in solid tumor oncology, despite recent advances in cancer therapies which have led to improvements in survival for these patients.…
View article: Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma
Prognostic Features of Recurrent Midline and H3 K27M-Mutant Glioma Open
High-grade glial tumors represent the most morbid form of brain cancer [...]
View article: Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial Open
View article: Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions
Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions Open
PURPOSE Blood-based liquid biopsy has enabled minimally invasive molecular profiling in patients with solid tumors. For cancers of the CNS, however, the use of peripheral blood for cell-free DNA (cfDNA) detection and sequencing has proved …
View article: Supplementary Table S10 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S10 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation by pre-operative steroid exposure (exposed vs unexposed).
View article: Supplementary Table S6 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S6 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
List of genes included in bespoke NETosis gene set.
View article: Supplementary Table S8 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S8 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation for % neutrophil ccfDNA dichotomized at median.
View article: Supplementary Table S1 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S1 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
Representativeness of Study Participants
View article: Supplementary Table S4 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S4 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
Detailed assay results for each patient with GBM and no cancer controls (NCC).
View article: Data from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Data from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
Purpose:Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration…
View article: Supplementary Table S9 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S9 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation for plasma [citH3] dichotomized at median.
View article: Supplementary Figures S1-S14 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Figures S1-S14 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analys…
View article: Supplementary Table S5 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S5 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
List of all methylGSA results for (Gene Ontology,GO, gene sets) differential methylation comparing cluster 1 vs cluster 2 from unsupervised clustering of the plasma ccfDNA methylation results.
View article: Supplementary Table S3 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S3 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
Array consistent autosomal CpGs from which deconvolution signature was selected.
View article: Supplementary Table S2 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S2 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
Published reference methylomes used in deconvolution
View article: Supplementary Table S11 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S11 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
Correlation statistics for Olink-detected proteins compared to [citH3], % neutrophil cfDNA, and pre-operative steroid dose ranked from highest to lowest rho for association with [CitH3].
View article: Supplementary Table S7 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma
Supplementary Table S7 from Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma Open
List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation comparing patients in cluster 1 vs cluster 2 from unsupervised clustering of the tissue DNA methylation results.
View article: The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers
The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers Open
This study establishes clinically accessible imaging biomarkers that capture the molecular composition and oncogenic drivers of glioblastoma. These findings have potential implications for noninvasive tumor profiling, personalized therapie…
View article: Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model
Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model Open
Purpose: Early treatment response assessments are crucial, and the results are known to better correlate with prognosis and survival outcomes. The present study was conducted to differentiate true progression (TP) from pseudoprogression (P…
View article: Supplementary Figure S1 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Supplementary Figure S1 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
Supplementary Figure 1. CODEX panel and experimental procedure. CODEX panel used to identify tumor cell subpopulations, immune cell populations and key cellular markers. (B) Experimental workflow for 5 pre- and post-treatment FFPE samples.…
View article: Supplementary Table S2 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Supplementary Table S2 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
CODEX antibodies
View article: Supplementary Table S3 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Supplementary Table S3 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
Patient representativeness
View article: Supplementary Figure S5 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Supplementary Figure S5 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
Supplementary Figure 5. Cell Density Analyses. Comparison of defined cell populations in pre- and post-treatment tumor specimens via CODEX. (A) Each indicated cell type is shown as a percentage of total cells in each pre- and post-tumor sp…
View article: Supplementary Figure S7 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Supplementary Figure S7 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
Supplementary Figure 7. Cellular Neighborhood Analyses. Comparison of annotated cellular neighborhoods in pre- and post-treatment tumor samples via CODEX (color code as in Figure 4).
View article: Data from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Data from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
Purpose:Radiotherapy may enhance antitumor immune responses by several mechanisms, including induction of immunogenic cell death. We performed a phase 2 study of pembrolizumab with re-irradiation in patients with recurrent glioblastoma.Pat…
View article: Supplementary Figure S4 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Supplementary Figure S4 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
Supplementary Figure 4. CODEX analysis of tumor PD-L1 expression patterns. (A) PD-L1 expression was detected in NCAM-1+ tumor cells surrounding by hypoxia region as detected by CA9 staining. (B) PD-L1 expression was also observed in GFAP+ …
View article: Supplementary Table S1 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma
Supplementary Table S1 from Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma Open
CODEX methods